ArticleEndocrine-related cancer2026
Defining the ATA-2025 'consider RAIT' zone in older patients with N1b PTC.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The secreted protein SPARCL1 suppresses tumor progression in papillary thyroid carcinoma via SLC3A2-mediated ferroptosis.Endocrine-related cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to quantify the cancer-specific death (CSD) benefit of radioactive iodine therapy (RAIT) in older patients with N1b differentiated thyroid carcinoma, a population designated by the ATA-2025 guideline as a 'consider RAIT' zone despite unproven mortality benefit, and to translate this recommendation into clinically actionable subgroups using a competing-risks framework. We used data from the Surveillance, Epidemiology, and End Results (SEER) programme (2004-2015) and analysed papillary thyroid carcinoma (PTC) cases aged ≥55 years with N1b, M0. After 1:1 propensity score matching, cumulative incidence function and Fine-Gray models evaluated associations between RAIT and CSD. Stratifications included tumour size, positive lymph node burden (PLN > 5), and ETE. A nomogram was developed for 1-, 3-, and 5-year CSD prediction, and absolute risk reduction (ARR) and number needed to treat (NNT) were estimated. Among 1,142 patients, 648 were matched (n = 324/group; median follow-up = 69 months). Five-year CSD was 14.1% without RAIT versus 5.1% with RAIT (P = 0.001), yielding ARR ≈ 9% and NNT ≈ 11. RAIT was independently protective (SHR 0.33, 95% CI: 0.14-0.76). Benefit concentrated in tumours 2-4 cm, PLN > 5, and ETE-positive strata. The nomogram showed strong discrimination and calibration. In patients aged ≥55 years with N1b PTC, RAIT confers measurable mortality benefit, most evident in 2-4 cm, PLN > 5, or ETE-positive disease. Integrating ARR, NNT, and a validated nomogram, this study converts the conceptual 'consider RAIT' into clinically actionable 'RAIT-favoured' and 'RAIT-optional' pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.